Discussing the FIREFLY-1 pediatric low-grade glioma data with Day One Bio at #ASCO23
- blonca9
- Jun 5, 2023
- 1 min read
Updated: Jun 15, 2023
Day One Bio CEO Jeremy Bender describes tovorafenib FIREFLY-1 trial result and Day One’s Plan to seek an accelerated approval for the drug.